We are excited to announce the launch of MyoMax™, a groundbreaking maturation media designed to enhance the maturity of iPSC-derived ventricular cardiomyocytes (CMs).
We developed MyoMax in response to findings in the literature1, and feedback from the market. We heard from scientists working in the field that immature CMs do not accurately recapitulate the response of adult CMs in cardiotoxicity and disease modelling studies, and so we decided to see how we could help.
The result was MyoMax, a new add-on media that addresses the critical limitations of current in vitro cardiac models by fostering the development of more mature, more physiologically relevant CMs, ultimately improving the accuracy and reliability of cardiotoxicity studies and drug development.
The problem with working with immature cardiomyocytes
Current iPSC-based models used for cardiotoxicity studies and disease modeling often suffer from the functional immaturity of the cardiomyocytes. These cells typically resemble fetal developmental states, leading to inaccurate drug responses and compromised phenotypic representations. MyoMax™ tackles this challenge by providing a specialized metabolic environment that promotes the development of more mature CMs, which more faithfully recapitulate the responses of adult cardiac tissue.
Modeling using more mature iPSC-derived cardiomyocytes
More mature CMs more faithfully recapitulate the response of adult CMs to cardiotoxic compounds, producing more robust in vitro models and enhancing confidence in data outputs.
A more mature phenotype in iPSC-CMs is evidenced by:
- Morphology: Increased numbers of rod-shaped cells, with superior sarcomere alignment.
- Marker Expression: The expression of key maturity markers and absence of immaturity markers
- Metabolic Shift: More mature CMs undergo a shift from glucose to fatty acid metabolism
- Electrophysiology: shorter action potential durations and faster conduction velocities closely reflect the electrophysiological properties of mature cardiac tissue.
By using more mature CMs, researchers can generate more physiologically relevant data, leading to more robust and reliable results in cardiotoxicity screening and drug development.
MyoMax™: enhanced metabolic maturation of human iPSC-derived ventricular cardiomyocytes
MyoMax offers a solution for a wide range of cardiac research and screening applications. This new add-on media is designed for use with axoCells ventricular cardiomyocytes.
